Loading clinical trials...
Loading clinical trials...
To evaluate the efficacy, safety and tolerability of maintenance therapy with BGB-290(Pamiparib) versus placebo in Chinese participants with recurrent ovarian cancer who achieved a complete response (...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
BeiGene
NCT07042802 · Ovarian Cancer
NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more
NCT06997029 · Advanced Solid Tumor, Advanced Breast Cancer, and more
Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital
Hefei, Anhui
Peking University First Hospital
Beijing, Beijing Municipality
Beijing Cancer Hospital
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions